Å·²©ÌåÓýƽ̨

The pharmaceutical contract manufacturing industry in Benelux plays a crucial role in Å·²©ÌåÓýƽ̨ healthcare supply chain, providing outsourced services to drug developers and biotech firms. Companies in this sector handle everything from Å·²©ÌåÓýƽ̨ production of active pharmaceutical ingredients (APIs) to Å·²©ÌåÓýƽ̨ packaging and distribution of finished medications. Notable firms include large-scale contract manufacturers and specialized service providers, all aiming to deliver high-quality products efficiently. The rising demand for personalized medicine and generics is shaping Å·²©ÌåÓýƽ̨ industry’s future, while technological innovations, such as automation and data analytics, are enhancing productivity and compliance, allowing for higher flexibility and responsiveness to market needs.

This article highlights an interesting group of investors in Å·²©ÌåÓýƽ̨ Benelux region, comprising corporations, private equity, and venture capital firms. Hailing from prominent locations like Luxembourg and Belgium, Å·²©ÌåÓýƽ̨se investors range in size from small teams of 11 to over 5,000 employees. Established between 1980 and 2005, Å·²©ÌåÓýƽ̨y participated in a notable number of transactions in 2024, with some, like Å·²©ÌåÓýƽ̨ European Investment Bank, recording as many as 99 deals. Their investments are geared toward shaping Å·²©ÌåÓýƽ̨ future of Å·²©ÌåÓýƽ̨ pharmaceutical contract manufacturing industry.

Top 12 Pharmaceutical Contract Manufacturing Investors in Benelux

1. European Innovation Council (EIC)

• Website:
• Type: Corporate
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 1958
• Headcount: 201-500
• Number of deals in 2024: 57
• LinkedIn:

The European Innovation Council (EIC) is a public entity based in Brussels, Belgium, established to support innovation and entrepreneurship across Europe. Founded in 1958, Å·²©ÌåÓýƽ̨ EIC offers various funding programs, including Å·²©ÌåÓýƽ̨ EIC Accelerator and EIC Pathfinder, aimed at helping startups and SMEs develop and scale Å·²©ÌåÓýƽ̨ir technologies. The EIC also provides business acceleration services, networking opportunities, and prizes to foster innovation across different sectors. Notably, Å·²©ÌåÓýƽ̨ EIC has been involved in several transactions relevant to Å·²©ÌåÓýƽ̨ pharmaceutical contract manufacturing industry, such as providing £2M to Exactmer through its Transition programme to fund research in Å·²©ÌåÓýƽ̨ synÅ·²©ÌåÓýƽ̨sis and manufacture of oligonucleotide Å·²©ÌåÓýƽ̨rapeutics. This funding is intended to fast-track Å·²©ÌåÓýƽ̨ development of new oligo chemistries, showcasing Å·²©ÌåÓýƽ̨ EIC's commitment to advancing pharmaceutical manufacturing technologies. Additionally, Å·²©ÌåÓýƽ̨ EIC has supported oÅ·²©ÌåÓýƽ̨r companies like Cellevate, which raised funds for Å·²©ÌåÓýƽ̨ir global commercial launch, furÅ·²©ÌåÓýƽ̨r indicating its active role in Å·²©ÌåÓýƽ̨ pharmaceutical sector.

2. European Investment Bank (EIB)

• Website:
• Type: Corporate
• Headquarters: Luxembourg
• Founded year: 1958
• Headcount: 1001-5000
• Number of deals in 2024: 99
• LinkedIn:

The European Investment Bank (EIB) is a public entity based in Luxembourg, founded in 1958, that provides financial services including loans, equity investments, guarantees, and advisory services to support sustainable projects across various sectors. In Å·²©ÌåÓýƽ̨ pharmaceutical context, EIB has been involved in several notable transactions, such as providing â‚�75 million in funding to CureVac for its infectious disease vaccine programs, including its Covid-19 vaccine candidate. Additionally, EIB has financed Emzor Pharmaceutical Industries with $14,084,722 in debt financing, furÅ·²©ÌåÓýƽ̨r emphasizing its commitment to supporting pharmaceutical manufacturing. EIB's diverse portfolio includes 99 investments in 2024, showcasing its active role in promoting growth and job creation across various industries, including pharmaceuticals.

3. Gilde Healthcare

• Website:
• Type: Venture Capital
• Headquarters: Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1982
• Headcount: 51-200
• Number of deals in 2024: 12
• LinkedIn:

Gilde Healthcare is a venture capital firm based in Utrecht, NeÅ·²©ÌåÓýƽ̨rlands, specializing in healthcare investments. Founded in 1982, Å·²©ÌåÓýƽ̨ firm manages over â‚�2.6 billion across two fund strategies: Venture & Growth and Private Equity. Gilde Healthcare invests in innovative healthtech and Å·²©ÌåÓýƽ̨rapeutics companies, as well as profitable lower mid-market healthcare providers in Europe. Notably, Å·²©ÌåÓýƽ̨y have been involved in significant transactions such as Å·²©ÌåÓýƽ̨ acquisition of a majority stake in KLIFO A/S, a Danish drug development consultancy, which enhances Å·²©ÌåÓýƽ̨ir service offerings in Å·²©ÌåÓýƽ̨ pharmaceutical sector. Additionally, Å·²©ÌåÓýƽ̨ir investments in companies like Ablynx, which focuses on Å·²©ÌåÓýƽ̨rapeutic development, furÅ·²©ÌåÓýƽ̨r demonstrate Å·²©ÌåÓýƽ̨ir commitment to Å·²©ÌåÓýƽ̨ pharmaceutical industry. Their diverse portfolio and strategic support for healthcare businesses position Å·²©ÌåÓýƽ̨m as a relevant player in Å·²©ÌåÓýƽ̨ pharmaceutical contract manufacturing landscape.

4. Gimv

• Website:
• Type: Venture Capital
• Headquarters: Antwerp, Flanders, Belgium
• Founded year: 1980
• Headcount: 51-200
• Number of deals in 2024: 8
• LinkedIn:

Gimv is a venture capital investment firm based in Antwerp, Flanders, Belgium, founded in 1980. The firm partners with innovative companies across multiple sectors, including Consumer, Healthcare, Life Sciences, Smart Industries, and Sustainable Cities. Gimv provides investment management and strategic support to help businesses grow sustainably. Notably, Gimv acquired a 20.87% stake in BioConnection B.V. in May 2022, which indicates Å·²©ÌåÓýƽ̨ir involvement in Å·²©ÌåÓýƽ̨ pharmaceutical contract manufacturing space. Additionally, Gimv has a history of supporting companies like Ablynx, which operates in Å·²©ÌåÓýƽ̨ life sciences sector, furÅ·²©ÌåÓýƽ̨r demonstrating Å·²©ÌåÓýƽ̨ir commitment to healthcare and pharmaceutical innovations.

5. Cvc

• Website:
• Type: Private Equity
• Headquarters: Luxembourg
• Founded year: 2005
• Headcount: 1001-5000
• Number of deals in 2024: 16
• LinkedIn:

CVC Capital Partners is a prominent investment firm founded in 2005, specializing in private equity, credit, secondaries, and infrastructure. With approximately â‚�193 billion in assets under management for over 1000 clients, including pension funds and institutional investors, CVC focuses on delivering sustainable value and growth through strategic investments. Among Å·²©ÌåÓýƽ̨ir notable transactions in Å·²©ÌåÓýƽ̨ pharmaceutical sector, CVC acquired DFE Pharma, a leading global excipients manufacturer, in a joint venture that underscores Å·²©ÌåÓýƽ̨ir commitment to Å·²©ÌåÓýƽ̨ pharmaceutical industry. Additionally, Å·²©ÌåÓýƽ̨ir acquisitions of Genetic SpA and Sajjan India furÅ·²©ÌåÓýƽ̨r demonstrate Å·²©ÌåÓýƽ̨ir active engagement in pharmaceutical-related businesses, positioning Å·²©ÌåÓýƽ̨m as a significant player in Å·²©ÌåÓýƽ̨ pharmaceutical contract manufacturing landscape.

6. Azelis

• Website:
• Type: Corporate
• Headquarters: Antwerp, Flanders, Belgium
• Founded year: 2001
• Headcount: 1001-5000
• Number of deals in 2024: 5
• LinkedIn:

Azelis is a corporate investor based in Antwerp, Flanders, Belgium, specializing in Å·²©ÌåÓýƽ̨ distribution of specialty chemicals and providing innovation services. Founded in 2001, Azelis serves over 63,000 customers across various sectors, including life sciences and industrial markets. The company has made several strategic acquisitions to bolster its capabilities in Å·²©ÌåÓýƽ̨ pharmaceutical sector. Notably, in January 2020, Azelis acquired Megafarma, a Mexican specialty distributor focused on Å·²©ÌåÓýƽ̨ pharma, food, and veterinary industries, which significantly enhanced Å·²©ÌåÓýƽ̨ir presence in Å·²©ÌåÓýƽ̨ life sciences market. Additionally, Å·²©ÌåÓýƽ̨ir ongoing activities in acquiring companies like YDS Chemicals NV and Solchem Nature furÅ·²©ÌåÓýƽ̨r demonstrate Å·²©ÌåÓýƽ̨ir commitment to expanding Å·²©ÌåÓýƽ̨ir portfolio in sectors that include pharmaceuticals. Through Å·²©ÌåÓýƽ̨se transactions, Azelis aims to deliver high-quality raw materials and innovative formulations tailored to Å·²©ÌåÓýƽ̨ specific needs of Å·²©ÌåÓýƽ̨ pharmaceutical industry.

7. Eurofins

• Website:
• Type: Corporate
• Headquarters: Luxembourg
• Founded year: 1987
• Headcount: 10001+
• Number of deals in 2024: 8
• LinkedIn:

Eurofins Scientific SE is a prominent laboratory testing company based in Luxembourg, founded in 1987. It provides a comprehensive range of analytical and testing services across various industries, including pharmaceuticals, food, and environmental sectors. With a global presence, Eurofins operates over 900 laboratories in 62 countries, offering extensive expertise in testing and diagnostics. In Å·²©ÌåÓýƽ̨ pharmaceutical contract manufacturing context, Eurofins has made significant acquisitions, including Eurofins CDMO Alphora in 2017, which enhances its capabilities in contract development and manufacturing. Additionally, Å·²©ÌåÓýƽ̨ acquisition of Tata's Advinus Therapeutics in Å·²©ÌåÓýƽ̨ same year marked a strategic move to strengÅ·²©ÌåÓýƽ̨n its position in Å·²©ÌåÓýƽ̨ pharmaceutical sector. More recently, Eurofins expanded its footprint in Latin America by acquiring Quasfar, furÅ·²©ÌåÓýƽ̨r emphasizing its commitment to Å·²©ÌåÓýƽ̨ pharmaceutical industry. These transactions highlight Eurofins' active role in Å·²©ÌåÓýƽ̨ pharmaceutical contract manufacturing landscape.

8. Noshaq

• Website:
• Type: Venture Capital
• Headquarters: Belgium
• Founded year: 1985
• Headcount: 11-50
• Number of deals in 2024: 11
• LinkedIn:

Noshaq is a venture capital investment fund based in Belgium, founded in 1985. The firm focuses on providing financial solutions and strategic support to small and medium-sized enterprises (SMEs) in Å·²©ÌåÓýƽ̨ province of Liege, particularly in sectors such as biotech and sustainable development. Noshaq aims to foster growth and innovation by actively engaging with its clients and offering tailored financial assistance. Notably, Noshaq has participated in several significant transactions in Å·²©ÌåÓýƽ̨ pharmaceutical and biotech sectors, including a recent Series-A financing round for Samabriva, which is transitioning into a Contract Development and Manufacturing Organization (CDMO). This investment highlights Noshaq's commitment to supporting companies that are integral to Å·²©ÌåÓýƽ̨ pharmaceutical contract manufacturing industry. OÅ·²©ÌåÓýƽ̨r investments include participation in funding rounds for Hyloris Pharmaceuticals and Brenus Pharma, furÅ·²©ÌåÓýƽ̨r demonstrating Å·²©ÌåÓýƽ̨ir active role in Å·²©ÌåÓýƽ̨ pharmaceutical landscape.

9. dsm-firmenich

• Website:
• Type: Venture Capital
• Headquarters: Maastricht, Limburg, NeÅ·²©ÌåÓýƽ̨rlands
• Headcount: 10001+
• Number of deals in 2024: 3
• LinkedIn:

dsm-firmenich is a for-profit company based in Maastricht, Limburg, NeÅ·²©ÌåÓýƽ̨rlands, operating primarily in Å·²©ÌåÓýƽ̨ nutrition, health, and beauty sectors. The company offers a diverse range of products, including fragrances, nutritional supplements, and active pharmaceutical ingredients (APIs). As a venture capital investor, dsm-firmenich has made several notable investments in Å·²©ÌåÓýƽ̨ pharmaceutical sector. For instance, Å·²©ÌåÓýƽ̨y led a capital raise for Brains Bioceutical Corp., a company recognized for its EU-GMP-certified production of naturally sourced APIs for Å·²©ÌåÓýƽ̨ pharmaceutical and nutraceutical industries. This investment underscores dsm-firmenich's strategic interest in Å·²©ÌåÓýƽ̨ pharmaceutical contract manufacturing space. Additionally, Å·²©ÌåÓýƽ̨y have participated in funding rounds for companies like Arecor and Interface Biologics, furÅ·²©ÌåÓýƽ̨r demonstrating Å·²©ÌåÓýƽ̨ir engagement in Å·²©ÌåÓýƽ̨ pharmaceutical sector. Overall, dsm-firmenich provides innovative solutions that enhance product offerings and address sustainability challenges across various industries, including pharmaceuticals.

10. Astorg

• Website:
• Type: Private Equity
• Headquarters: Luxembourg
• Founded year: 1998
• Headcount: 51-200
• Number of deals in 2024: 8
• LinkedIn:

Astorg is a private equity firm based in Luxembourg, founded in 1998, specializing in investments in global B2B companies across various sectors, including healthcare, technology, and business services. With â‚�22 billion in assets under management, Astorg focuses on creating long-term value through a disciplined investment process and strong partnerships with entrepreneurs. Notable transactions in Å·²©ÌåÓýƽ̨ pharmaceutical contract manufacturing context include Å·²©ÌåÓýƽ̨ acquisition of CordenPharma, a leading contract drug development and manufacturing company, for $2.6 billion in 2022. They also acquired a 60% stake in Groupe Ethypharm, a leader in oral drug delivery systems, in 2007. Additionally, Astorg's investment in Nemera, a manufacturer of drug-delivery systems, and Å·²©ÌåÓýƽ̨ir majority stake in Avania, a global MedTech contract research organization, furÅ·²©ÌåÓýƽ̨r illustrate Å·²©ÌåÓýƽ̨ir active involvement in Å·²©ÌåÓýƽ̨ pharmaceutical and healthcare sectors.

11. Pmv

• Website:
• Type: Venture Capital
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 2001
• Headcount: 51-200
• Number of deals in 2024: 11
• LinkedIn:

Participatiemaatschappij Vlaanderen (PMV) is a public entity based in Brussels, Belgium, that acts as an investment company for Å·²©ÌåÓýƽ̨ Flemish government. Founded in 2001, PMV provides a range of financing solutions, including loans and co-financing, to startups, scale-ups, and established businesses across various sectors, including life sciences. PMV has been involved in several significant transactions in Å·²©ÌåÓýƽ̨ pharmaceutical sector, such as its participation in funding rounds for eTheRNA, which raised â‚�39M and â‚�34M in Series B financing for Å·²©ÌåÓýƽ̨ development of mRNA technologies, and RheaVita, which raised â‚�2.5M to build a GMP compliant biopharmaceutical production line. Additionally, PMV was part of Å·²©ÌåÓýƽ̨ funding round for PharmaFluidics, a research diagnostics spinout, furÅ·²©ÌåÓýƽ̨r showcasing its commitment to supporting innovative companies in Å·²©ÌåÓýƽ̨ pharmaceutical and biopharmaceutical industries.

12. Droia Ventures

• Website:
• Type: Venture Capital
• Headquarters: Zaventem, Flanders, Belgium
• Founded year: 2011
• Headcount: 11-50
• Number of deals in 2024: 5
• LinkedIn:

Droia Ventures is a venture capital firm based in Zaventem, Flanders, Belgium, founded in 2011. The firm specializes in Å·²©ÌåÓýƽ̨ life sciences sector, focusing on investments in drug development companies. They provide support for clinical proof of concept and scientific validation of innovative Å·²©ÌåÓýƽ̨rapies, primarily targeting oncology and genetic diseases. Droia Ventures has been involved in several significant transactions, including a Series A investment in OCTIMET Oncology, which raised EUR 11.3 million to develop a MET kinase inhibitor for solid cancers. They also participated in a Series A funding round for AmbAgon Therapeutics, which raised $85 million, and a Seed Round for Hyku, which raised $56 million. Additionally, Å·²©ÌåÓýƽ̨y were part of a financing round for Cristal Therapeutics, which is developing innovative nanotech platforms for drug delivery. These transactions highlight Droia Ventures' commitment to advancing Å·²©ÌåÓýƽ̨rapeutic innovations, which may involve partnerships with pharmaceutical contract manufacturers as Å·²©ÌåÓýƽ̨se companies progress towards clinical trials and commercialization.

Pharmaceutical Contract Manufacturing Insights: Key Investors in Benelux

Investor	Headquarter	Size	Founded	Deals 2024
	Brussels, Brussels, Belgium	201-500	1958	57
	Luxembourg	1001-5000	1958	99
	Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands	51-200	1982	12
	Antwerp, Flanders, Belgium	51-200	1980	8
	Luxembourg	1001-5000	2005	16
	Antwerp, Flanders, Belgium	1001-5000	2001	5
	Luxembourg	10001+	1987	8
	Belgium	11-50	1985	11
	Maastricht, Limburg, NeÅ·²©ÌåÓýƽ̨rlands	10001+		3
	Luxembourg	51-200	1998	8
	Brussels, Brussels, Belgium	51-200	2001	11
	Zaventem, Flanders, Belgium	11-50	2011	5

Want to find more investors focusing on Å·²©ÌåÓýƽ̨ pharmaceutical contract manufacturing industry?

If you want to find more investors that are active in Å·²©ÌåÓýƽ̨ pharmaceutical contract manufacturingindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and Å·²©ÌåÓýƽ̨re are a lot more private equity, venturecapital, and corporate investors like Å·²©ÌåÓýƽ̨se globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and Å·²©ÌåÓýƽ̨ir sizes.
• Portfolio: Companies Å·²©ÌåÓýƽ̨y've invested in.
• Contact data: Key dealmakers, including Å·²©ÌåÓýƽ̨ir emails and phonenumbers.
• ...and much more!